Besser R E, Feikin D R, Eberhart-Phillips J E, Mascola L, Griffin P M
Foodborne and Diarrheal Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga 30333.
JAMA. 1994 Oct 19;272(15):1203-5.
To assess cholera recognition and treatment by US health care workers in the largest cholera outbreak in the United States this century.
We reviewed the medical records of passengers from a flight on which a cholera outbreak occurred. To determine the availability of oral rehydration solutions, we surveyed treatment facilities and referral pharmacies.
On February 14, 1992, more than 100 passengers on a flight from South America to Los Angeles, Calif, were infected with toxigenic Vibrio cholerae O1.
Fifty-four of 67 passengers who sought care in California and Nevada.
We reviewed the records of 54 passengers, including 39 with diarrhea and 15 without symptoms. All 17 persons who sought treatment before the outbreak was widely reported by the media had diarrhea. For 12 of these persons, recent travel to South America was noted, but only those four whose records listed cholera as a possible diagnosis were immediately hospitalized. Seven sought care again within 3 days; three were dehydrated, two of these three were hospitalized, and one of these two died. None of the 26 patients suspected to have cholera received appropriate fluids; severely dehydrated patients did not receive Ringer's lactate solution and those not severely dehydrated did not receive an oral rehydration solution. None of the facilities and pharmacies involved stocked World Health Organization oral rehydration salts solution, the preferred solution for treating cholera and other diarrheal diseases.
Treatment of cholera in the United States was suboptimal. Oral fluids appropriate for the treatment of cholera and other diarrheal diseases were generally unavailable. Widespread cholera in the developing world means that US physicians should be prepared to treat "imported" cases. Physicians evaluating patients with diarrhea should obtain a travel history, should consider cholera in patients returning from countries with endemic or epidemic cholera, and should instruct patients in appropriate use of World Health Organization oral rehydration salts solution or other oral rehydration solutions containing 75 to 90 mmol/L of sodium. Pharmacies and medical facilities should stock these solutions.
评估美国医护人员对本世纪美国最大规模霍乱疫情的识别与治疗情况。
我们查阅了一架发生霍乱疫情航班上乘客的病历。为确定口服补液溶液的可得性,我们对治疗机构和转诊药房进行了调查。
1992年2月14日,一架从南美洲飞往加利福尼亚州洛杉矶的航班上,100多名乘客感染了产毒性霍乱弧菌O1。
在加利福尼亚州和内华达州就医的67名乘客中的54名。
我们查阅了54名乘客的病历,其中39人有腹泻症状,15人无症状。在疫情被媒体广泛报道之前寻求治疗的17人中,所有人都有腹泻症状。其中12人有近期前往南美洲旅行的记录,但只有4名病历中列出霍乱可能诊断的患者立即住院。7人在3天内再次就医;3人脱水,其中2人住院,2人中1人死亡。26名疑似霍乱患者均未接受适当的补液治疗;严重脱水患者未接受乳酸林格液,未严重脱水患者未接受口服补液溶液。所涉机构和药房均未储备世界卫生组织口服补液盐溶液,而这是治疗霍乱和其他腹泻病的首选溶液。
美国对霍乱的治疗并不理想。通常无法获得适合治疗霍乱和其他腹泻病的口服补液。发展中世界霍乱的广泛流行意味着美国医生应做好治疗“输入性”病例的准备。评估腹泻患者的医生应了解其旅行史,对于来自霍乱流行或暴发国家的患者应考虑霍乱,并应指导患者正确使用世界卫生组织口服补液盐溶液或其他含75至90 mmol/L钠的口服补液溶液。药房和医疗机构应储备这些溶液。